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1. Introduction 
Dyslipidemia is the major risk factors for macrovascular complications leading to 
cardiovascular disease (CVD) in type 2 diabetes mellitus (T2DM). In addition to this, 
endothelial dysfunction, platelet hyperactivity, impaired fibrinolytic balance and abnormal 
blood flow may accelerate atherosclerosis and increased risk of thrombotic vascular events 
(Colwell & Nesto, 2003). Macrovascular disease is the most common cause of morbidity and 
mortality in T2DM (Koskinen, 1998). Macrovascular disease is defined as illnesses affecting 
the larger arteries supplying the heart, brain, and the legs, thereby causing ischemic heart 
disease, cerebrovascular disease, and peripheral vascular disease (Thompson, 1999). In 
patients with diabetes, alteration in distribution of lipid increased risk of atherosclerosis. 
Specifically, insulin resistance and insulin deficiency was identified as phenotype of 
dyslipidemia in diabetes mellitus (Taskinen, 2003; Krauss & Siri, 2004; Chahil & Ginsberg, 
2006). This was characterized with high plasma triglyceride level, low HDL cholesterol level 
and increased level of small dense LDL-cholesterol (Mooradian, 2008). In these patient also, 
the increment of free fatty-acid release is due to insulin resistance. With the presence of 
adequate glycogen stores in the liver, this will promote triglyceride production, which 
stimulates the secretion of apolipoprotein B (Apo B) and VLDL cholesterol (Mooradian, 
2008). Hepatic production of VLDL cholesterol is enhanced due to disability of insulin to 
inhibit the release of free fatty-acid. Low HDL cholesterol levels were also associated with 
hyperinsulinemia. There are several associations between dyslipidemia and the increased 
risk of cardiovascular disease in patients with type 2 diabetes mellitus. Low HDL cholesterol 
and increased triglyceride levels may contribute to the increased risk of cardiovascular 
disease. In conjunction with increased small dense LDL cholesterol and low HDL cholesterol 
levels, further evidence suggests that acceleration of atherosclerosis in diabetes mellitus and 
insulin-resistant conditions is regulated by hypertriglyceridemia. Nevertheless, the 
association between LDL cholesterol and CHD risk is stronger compared to the association 
between hypertriglyceridemia and CHD risk. Type 2 diabetes is also associated with insulin 
resistance and hyperinsulinemia or syndrome X comprises hypertension, dyslipidemia, 
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decreased fibrinolysis and increased procoagulation factors (Serrano Rios, 1998). Besides 
dyslipidemia, platelet abnormalities contributed significantly to increased risk of CVD in 
these patients. In patients with type 2 diabetes, the platelet abnormalities are due to 
increased platelet aggregability and adhesiveness (Colwell & Nesto, 2003) and enhanced 
platelet aggregation activity may precede development of CVD (Halushka et al. 1981, 
Mandal et al. 1993). It has been well known that management of dyslipidemia in diabetes 
mellitus includes lifestyle changes such as increased physical activity and dietary 
modifications. Besides, various antihyperlipidemic agents have been utilized for this 
purpose. In contrast, antiplatelet agents are recommended mainly for primary and 
secondary prevention for cardiovascular disease in T2DM. Dyslipidemia is categorized as 
one of the cardiovascular risk factors besides others (family history CHD, hypertension, 
smoking, albuminuria) (American Diabetes Association, 2011). Patients with T2DM and 
having dyslipidemia are eligible for primary prevention of CVD with antiplatelet agents. 
This chapter will discuss on different types of antiplatelet agents used as primary 
prevention of cardiovascular disease in patients with T2DM. It will also emphasize 
appropriate selection of antiplatelet agents pertaining to clinical conditions of patients with 
T2DM and dyslipidemia. 
2. Pathophysiology of dyslipidemia and platelet abnormalities in type 2 
diabetes mellitus 
Atherogenic dyslipidemia is characterized by three lipoprotein abnormalities: elevated 
VLDL, small LDL and decreased HDL cholesterol levels, named as atherogenic lipoprotein 
phenotype (Grundy, 1998). In patients with type 2 diabetes, the prothrombotic state is 
characterized by increased fibrinogen levels (Imperatore et al 1998), increased plasminogen 
activator inhibitor (PAI)-1 (Byberg et al., 1998) and abnormalities in platelet function 
(Trovati et al., 1988). The reason for three aforementioned phenotypes in athrogenic 
dyslipidemia is the increased free fatty-acid release from insulin-resistant fat cells (Taskinen, 
2003; Krauss & Siri, 2004; Chahil & Ginsberg, 2006). The increased flux of free fatty acids 
into the liver in the presence of adequate glycogen stores promotes triglyceride production, 
which in turn stimulates the secretion of apolipoprotein B (ApoB) and VLDL cholesterol 
(Mooradian, 2008). The impaired ability of insulin to inhibit free fatty-acid release leads to 
enhanced hepatic VLDL cholesterol production (Frayn, 2001) which correlates with the 
degree of hepatic fat accumulation (Adiels et al., 2007). The increased number of plasma 
VLDL cholesterol and triglyceride levels decrease the level of HDL cholesterol and increase 
the concentration of small dense LDL cholesterol (Mooradian, 2008).  
Platelet activation commenced with binding of thrombogenic substances (collagen, 
thrombin, components of atheromatous plaque) to receptors located on the platelet surface 
(Colwell & Nesto, 2003). Receptor binding triggers a series of events that include hydrolysis 
of membrane phospholipids, mobilization of intracellular calcium, and phosphorylation of 
important intracellular proteins (Colwell & Nesto, 2003). There are several platelet 
abnormalities seen in diabetes patients. Abnormalities of thromboxane A2 (TXA2) 
production were among the earliest abnormalities in platelets of diabetes patients. TXA2 is a 
potent activator and its synthesis is suppressed by aspirin (Natarajan et al., 2008). Platelets 
from patients with type 2 diabetes mellitus found to have increased expression of adhesion 
molecules CD31, CD36, CD49b, CD62P and CD63 (Eibl et al., 2004). Glycemic control 
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improvement led to a significant decline in their expression (Eibl et al., 2004). In type 2 
diabetes patients, platelets increased surface expressionof GP Ib and GP IIb/IIIa (Vinik et al., 
2001). GP Ib mediates binding to von Willebrand factor (vWf) which is important in platelet-
dependent thrombogenesis (Natarajan et al., 2008). Increased expression of GP IIb/IIIa on 
platelet surfaces leads to enhanced fibrinogen binding, platelet cross-linking and 
thrombogenesis (Colwell & Nesto, 2003). In patients with type 2 diabetes, decreased platelet 
insulin receptor number and affinity responsible for platelet hyperactivity (Vinik et al., 
2001). Platelets have been shown to be targets of insulin action as they act as functional 
insulin receptor for insulin binding and autophosphorylation (Vinik et al., 2001). Insulin 
reduces platelet responses to the agonists’ adenosine diphosphate (ADP), collagen, 
thrombin, arachidonate and platelet-activating factor. (Natarajan et al., 2008). In patients 
with type 2 diabetes also, platelets show disordered calcium homeostasis (Li et al., 2001). 
This may cause hyperactivity including platelet shape change, secretion, aggregation and 
thromboxane formation (Beckman et al., 2002). Furthermore, the deficiency of magnesium in 
diabetes has been associated with platelet hyperaggregability and adhesiveness (Gawaz et 
al., 1994). In type 2 diabetes patients, the reduced vascular synthesis of the anti-aggregants 
prostacyclin and nitric oxide by endothelium, shift the balance towards aggregation and 
vasoconstriction (Vinik et al., 2001; Ferroni et al., 2004). In type 2 diabetes patients with 
acute hyperglycaemia, shear stress-induced platelet activation and P-selection expression 
(Natarajan et al., 2008). Hyperglycaemia also causes non-enzymatic glycation of platelet 
membrane proteins resulting in changes in protein structure and conformation, as well as 
alterations of membrane lipid dynamics (Brownlee et al., 1988; Winocour et al., 1992). This 
could result in enhanced expression of certain crucial platelet receptors, for instance,  
P-selectin and GP IIb/IIIa, thus altering platelet activity (Ferroni et al., 2004). Glycated LDL 
causes an increase in intracellular calcium concentration and platelet nitric oxide (NO) 
production, as well as inhibition of the platelet membrane Na+/K+-adenosine 
triphosphatase (Na+/K+-ATPase) activity (Ferroni et al., 2004). 
3. Implications of dyslipidemia and platelet abnormality in type 2 diabetes 
mellitus 
In patients with type 2 diabetes mellitus, low HDL cholesterol and high triglyceride levels 
might contribute to the increased risk of cardiovascular disease (Mooradian, 2008). Based on 
the Expert panel on Detection, Evaluation and Treatment of High Blood Cholesterol in 
Adults (2011), hypertriglyceridemia, increased small dense LDL cholesterol and low HDL 
cholesterol found to be important in accelerating atherosclerosis in diabetes mellitus and 
insulin-resistant conditions. Abnormal platelet function is another important risk factors for 
cardiovascular disease in patients with diabetes (Colwell & Nesto, 2003). Atherosclerosis 
and thrombosis contribute significantly to the increased cardiovascular risk of diabetic 
patients (Colwell, 1997). The majority of ischemic coronary and cerebrovascular events are 
precipitated by vessel occlusion caused by atherosclerotic plaque disruption, platelet 
aggregation, platelet adhesion and thrombosis (Colwell & Nesto, 2003). Several systems that 
involved vasculature such as platelet, endothelial function, coagulation and fibrinolysis are 
impaired in patients with diabetes (Jokl & Colwell, 1997). Furthermore, increased platelet 
aggregability and adhesiveness are due to reduce membrane fluidity, increased intracellular 
Ca2+ and decreased intracellular Mg2+, increased arachidonic acid metabolism, increased 
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TXA2 synthesis, decreased prostacyclin production, decreased NO production, decreased 
antioxidant levels and increased expression of activation-dependent adhesion molecules 
(Halushka et al., 1981; Mayfield et al., 1985; Watala et al., 1998; Martina et al., 1998; Trovati 
et al., 1997; Sarji et al., 1979; Tschoepe, et al., 1997; Leet et al., 1981). For patients with T2DM, 
the presence of dyslipidemia and platelet hyperactivity justifies the use of antiplatelet agents 
as primary prevention strategy of CVD. 
4. Role of antiplatelet agents in primary prevention of CVD 
Increased physical activity, dietary modifications and pharmacologic interventions are the 
key methods in management of dyslipidemia in type 2 diabetes mellitus (Mooradian, 2008). 
The Antithrombotic Trialists’ Collaboration meta-analysis found that antiplatelet therapy 
reduces the relative risk of any serious vascular event by 25% in patients at high risk for a 
cardiovascular (CV) event (Antithrombotic Trialist’ Collaboration, 2002). Antiplatelet agents 
are used for primary and secondary prevention of CVD in type 2 diabetes mellitus patients. 
Antiplatelet therapy is needed in the management of diabetes mellitus because there is an 
increase of platelet aggregability and adhesiveness due to platelet and endothelial 
dysfunction, impaired coagulation cascade, and fibrinolysis process among diabetic 
individuals compared to nondiabetic individuals (Colwell & Nesto, 2003). Consequently, the 
balance in normal hemostasis is shifted to favor thrombosis and accelerated atherosclerosis 
and results in increasing CVD (Colwell & Nesto, 2003). For primary prevention of 
cardiovascular diseases, type 2 diabetes mellitus patients with high risk acquiring 
cardiovascular events such as those with family history of cardiovascular disease, 
hypertension, obesity (BMI > 30 kg/m2), smoking, dyslipidemia and albuminuria (Colwell, 
2004). Several types of antiplatelet agents is being utilized for prevention of CVD which 
including aspirin, ticlopidine, clopidogrel and glycoprotein (Gp) IIb-IIIa antagonist such as 
abciximab, eptifibatide and tirofiban (Patrono et al., 2004; American Diabetes Association, 
2006; Colwell & Nesto, 2003). Aspirin is one of the most common antiplatelet that been 
suggested in prevention of CVD in diabetes. Clopidogrel and ticlopidine are theinopyridine 
antiplatelet agents that generally suggested if patients are contraindicated to aspirin 
(American Diabetes Association, 2006). In contrast, Gp IIb-IIIa antagonist is usually given to 
diabetes patients who undergo precutaneous coronary intervention in order to intensify the 
antiplatelet therapy and to reduce the risk of procedure related thrombotic complication and 
reoccurrence of CV event (Patrono et al., 2004). 
5. Types of antiplatelet 
5.1 Aspirin 
Aspirin selectively and irreversibly acetylates the COX-1 enzyme, thereby blocking the 
formation of thromboxane A2 in platelets and leads to inability of platelet to resynthesize 
COX-1 (Patrono et al., 2005). Aspirin has been used as a primary strategy to prevent CVD in 
type 2 diabetes due to its effectiveness in atherosclerosis prevention is well established. 
Various meta-analyses studies and large scale randomized controlled trials in T2DM 
support that low-dose aspirin therapy should be prescribed as prevention strategy in T2DM, 
if the contraindication is not exist (Colwell, 2004). Low dose of aspirin inhibits thromboxane 
production by platelets but has little or no effects on other sites of platelet activity (Colwell 
& Nesto, 2003). Several randomized controlled trials had been designed to assess the 
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efficacy of aspirin in primary prevention of CVD which included Primary Prevention Project 
(PPP), US physicians’ Health Study (USPHS), Early Treatment of Diabetes Retinopathy 
Study (ETDRS), Hypertension Optimal Treatment Trial (HOT), British Male Doctors’ Trial 
(BMD) and the Thrombosis Prevention Trial (TPT) (Colwell & Nesto, 2003; Hayden et al., 
2002). In Primary Prevention Project (PPP), a low dose aspirin (100 mg/day) was evaluated 
for the prevention of cardiovascular events in individuals with one or more of the following 
conditions such as hypertension, hypercholesterolemia, diabetes, obese, family history of 
premature myocardial infarction or being elderly. After a mean of 3.6 years follow-up, 
aspirin was found to significantly lower the frequency of cardiovascular death (from 1.4 % 
to 0.8 %); relative risk (RR) 0.56 [confidence interval (CI) 0.31-.99] and total cardiovascular 
events (from 8.2 to 6.3% ; RR 0.77 [ 0.62-0.95] ). This trial involved large sample size (n = 
4495) with the largest proportion of patients with diabetes mellitus (17%) (Collaborative 
Group of the Primary Prevention Project, 2001). Overall, PPP provides evidence to prove the 
efficacy of aspirin in diabetes; though participants were not blinded and were not given 
placebo pills. Additionally, a meta-analysis done by Hayden et al., (2002) also rated the 
quality of PPP as “fair” if compared to the rest of studies. In addition to PPP, a 5 years 
primary prevention trial in 22 701 healthy men; included 533 men with diabetes was 
conducted in US Physicians’ Health Study (USPHS) in which a low-dose aspirin regimen 
(325 mg every other day) was given to treated group compared with placebo. A total of 44% 
significant risk reduction in CVD treated group was noted and the subgroup analyses in the 
diabetes reveals a reduction in myocardial infarction from 10.1 % (placebo) to 4.0 % 
(aspirin), yield a relative risk reduction of 0.39 for the diabetes men on aspirin therapy 
(Steering Committee of the Physicians’ Health Study Research Group, 1989). Researcher and 
participants were blinded in this trial. In contrast with PPP, women were included in the 
study populations (2583 out of 4495 sample sizes). Hence, this study was more reliable 
compared to previous ones even though only 2% of the study population was diagnosed 
with diabetes. The Hypertension Optimal Treatment Trial (HOT) also examined the effects 
of low dose of aspirin (75 mg/day) versus placebo in 18 790 hypertension patients and 8% of 
them had diabetes. Results showed that aspirin significantly reduce cardiovascular event by 
15% and myocardial infarction by 36% (Hansson et al., 1998). The HOT trial was another 
primary prevention study that included women, which was 46.6 % from total study 
population. Colwell (2004) commended that this study provided further evidence for the 
efficacy and safety of aspirin therapy in diabetes with systolic blood pressure less than 160 
mmHg. Hayden et al., (2002) was in agreement with Colwell (2004) and concluded that HOT 
was a “good” quality of trial in their meta-analysis. Despite that, these findings were 
mirrored by Early Treatment of Diabetes Retinopathy Study (ETDRS) where they reported 
that although aspirin did not prevent progression of retinopathy but it did produce a 
significant reduction in risk for myocardial infarction (28%) over 5 years (P=0.038). This 
study may viewed as mixed primary and secondary prevention trials since those enrolled 
had a history of myocardial infarction and less than 50% had elevated blood pressure and 
history of CVD (ETDRS Investigators 1992). Conversely, the British Male Doctors’ Trial 
(BMD) had conflicting results regarding aspirin effects in reducing the risk for myocardial 
infarction and adverse effects such as gastrointestinal bleeding and hemorrhagic stroke to 
diabetes patients. A total of 39 % of participants were discontinued therapy during the study 
due to adverse effect of aspirin (Hayden et al., 2002). Similar to PPP trial, participants in this 
study were not blinded thus results may be varies. Following this, a meta-analysis of these 
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five randomized clinical trials (except ETDRS) was performed by Hayden et al., (2002) and 
systematic reviews on nine articles about the effect of aspirin on gastrointestinal bleeding 
and hemorrhagic stroke were conducted. They concluded that the net benefit of aspirin 
increase with CV risk. Nonetheless, this meta-analysis was found to have selection bias due 
to exclusion of 2 large trials that examined the effects of aspirin in patients with diabetes or 
stable angina. Sanmuganathan et al., (2001) also reached similar estimates of the beneficial 
effects of aspirin in primary prevention of CVD. The Japanese Primary Prevention of 
Atherosclerosis With Aspirin for Diabetes (JPAD) trial was the first prospectively designed 
trial to evaluate the use of aspirin (81 mg or 100 mg) in the primary prevention of 
cardiovascular events in patients with type 2 diabetes (n = 2539) aged 30–85 years in Japan 
(Ogawa et al., 2008). Among patients aged > 65 years (n =1363), aspirin was associated with 
a 32% reduction in the risk of the primary end point (6.3 vs. 9.2%; P = 0.047). Furthermore, in 
aspirin-treated patients, the incidence of fatal coronary and cerebrovascular events was 
significantly lower by 90% (0.08 vs. 0.8%; P = 0.0037). Paradoxically, there were no 
differences in nonfatal coronary and cerebrovascular events. Aspirin was well tolerated, 
with no significant increase in the composite of hemorrhagic stroke and severe 
gastrointestinal bleeding (Angiolillo, 2009). The outcome of this study was in opposite with 
the current recommendations on aspirin usage in primary prevention of CVD in diabetes 
patients (Angiolillo, 2009). However, the ASCEND and ACCEPT-D study are two ongoing 
trials will provide further insights to the appropriateness of aspirin usage in primary 
prevention of CVD in patients with diabetes. Another recent trial (POPADAD), failed to 
show any benefit with aspirin or antioxidants in primary prevention of cardiovascular 
events (Belch, 2008). The outcome of the study could be due to small number of patients 
with low event rates. A study on the utilization of antiplatelet therapy in type 2 diabetes 
patients revealed that many of the eligible patients did not receive the drugs as primary 
prevention strategy for CVD (Huri et al., 2008). Therefore, the recommendations on aspirin 
usage in primary prevention of CVD in type 2 diabetes patients must be fully justified after 
taking consideration against the benefit versus risk of its use. In another words, the 
recommendations should be base on individual patients’ assessment and clinical judgment. 
Proper use of aspirin in primary prevention of CVD in type 2 diabetes patients may result in 
long-term benefits.  
5.2 Clopidogrel  
Clopidogrel is another type of antiplatelet agents used in primary prevention of CVD in 
type 2 diabetes when patients are intolerant to aspirin. It inhibits ADP-induced platelet 
aggregation by blocking the purinergic receptors and therefore prevents the activation of the 
GpIIb-IIIa receptor and subsequent binding to fibrinogen (Colwell & Nesto, 2003). 
Clopidogrel is preferable compared to ticlopidine because of its safety profile (Savi & 
Herbert, 2005; Bertrand et al., 2000). Nevertheless, the information regarding the usage of 
clopidogrel in primary prevention of CVD is limited than for secondary prevention of CVD 
in diabetes patients. Even though clopidogrel may be slightly more effective than aspirin, 
the size of any additional benefits is statistically uncertain and it has not been granted a 
claim of superiority against aspirin (Patrono et al., 2004). However, the publication of the 
Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) recently had led to 
FDA approval of a new indication for clopidogrel in patients with acute coronary 
syndromes without ST-segment elevation (Patrono et al., 2004).The CURE trial examined CV 
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outcomes with clopidogrel plus aspirin versus aspirin alone in patients with acute ischemic 
heart disease (IHD) (CURE Steering Committee, 2001). These findings demonstrated that 
clopidogrel has beneficial effects in patients with acute coronary syndromes without ST-
segment elevation thus can be generalized as the study sample size (n =12,562) was large 
and patients were recruited from 482 centers in 28 countries. This trial also showed that 
3.7% of patients in this combination therapy group had major bleeding and it was 
significant more compared with those solely on aspirin but there was no increase in life-
threatening bleeds (CURE Steering Committee, 2001). Hence, a loading dose of 300mg 
clopidogrel should be used in this setting followed by 75 mg daily (Patrono et al., 2004). 
Bhatt et al., (2002) concluded that clopidogrel is an effective drug for secondary prevention 
in diabetes. Therefore, previous studies clearly justified the use of dual anti platelet therapy 
with aspirin and clopidogrel for secondary prevention of CVD in diabetes patients. Its role 
in primary prevention of CVD in diabetes patients is vague since no study has directly 
measure the outcome for this purpose.  
5.3 Ticlopidine 
Ticlopidine also inhibit ADP-induced platelet aggregation with no direct effects on the 
metabolism of arachidonic acid (Patrono, 1998). It has slower antiplatelet effect compared 
with clopidogrel (Patrono et al., 2004). Ticlopidine in Microangiopathy of Diabetes (TIMAD) 
study was conducted by involving 435 patients with nonproliferative diabetes retinopathy 
to evaluate for its effects on macrovascular disease in diabetes patients. Patients were 
randomized to receive ticlopidine, 250 mg twice daily and were followed up to 3 years. 
Ticlopidine was found significantly reduced annual microaneurysm progression by 67% 
and overall progression of retinopathy was significantly less severe with ticlopidine 
(TIMAD Study Group, 1990). However, this study was not designed to evaluate effect of 
ticlopidine on cardiovascular events. There are limited studies done on effect of ticlopidine 
in prevention of CVD in diabetes. In contrast to clopidogrel, ticlopidine does not have an 
approved indication for patients with a recent myocardial infarction (Patrono et al., 2004). 
Even though ticlopidine has lower cost compared to clopidogrel, (Drug Formulary 
University Malaya Medical Centre, 2005; Patrono et al., 2004), its role in primary prevention 
of CVD in type 2 diabetes patients have not been established. 
5.4 Dipyridamole  
Dipyridamole inhibits platelet cyclic-3’,5’-adenosine monophosphate and cyclic-3’, 5’-
guanosine monophosphate phosphodiesterase (Natarajan et al. 2008). Overview of 25 trials 
among approximately 10000 high risks of CVD patients with the use of dipyridamole and 
aspirin, it was found that the addition of dipyridamole to aspirin has not been shown clearly 
to produce additional reductions in serious vascular events (Patrono et al., 2004). However, 
one of 25 trials suggested that there may be a worthwhile further reduction in stroke 
(Patrono et al. 2004). Patrono et al., (2004) also suggested that the combination of low dose 
aspirin and extended release dipyridamole (200 mg twice daily) is considered an acceptable 
option for initial therapy of patients with non-cardioembolic cerebral ischemic events and 
not in patients with ischemic heart attack. The benefits of dipyridamole in patients with 
diabetes have not been reported (Natarajan et al., 2008). Specifically, there are limited 
studies or trials conducted to examine the role of dipyridamole for primary and secondary 
prevention of CVD amongst T2DM patients.  
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5.5 GP IIb/IIIa inhibitors 
The platelet glycoprotein (GP) IIb/IIIa complex receptor antagonists block activity at the 
fibrinogen binding site on platelet (Colwell & Nesto, 2003). These agents are useful in type 2 
diabetes patients with acute coronary syndrome and in those undergoing percutaneous 
coronary interventions (Colwell & Nesto, 2003). These agents are administered intravenously 
with a rapid onset of action and short half-life (Natarajan et al., 2008). Numerous studies have 
been performed comparing various GP IIb/IIIa inhibitors. Currently, three different GP 
IIb/IIIa inhibitors (abciximab, eptifibatide, and tirofiban) are approved for clinical use. This 
group of drugs was mainly study for secondary prevention of CVD in diabetes patients. 
Evidence from three trials revealed that among 1,262 diabetes patients, use of these agents was 
associated with reduction in mortality from 4.5% to 2.5% (p=0.031) (Bhatt et al., 2000). In 
another meta-analysis of six large trials, with 6,458 patients with diabetes and acute coronary 
syndromes, GP IIb/IIIa inhibitor therapy was associated with a significant mortality reduction 
at 30 days, from 6.2% to 4.6% CI(0.59-0.92, p=0.007) (Roffi et al., 2001). Nonetheless, the role of 
GP IIb/IIIa inhibitors in primary prevention of CVD in type 2 diabetes mellitus has not been 
justified; therefore it is not recommended for this purpose. 
6. Appropriate selection of antiplatelet agents for primary prevention of CVD 
in type 2 diabetes patients 
Among all choices, there are considerations to be taken into account before types of 
antiplatelet agents chosen. According to American Diabetes Association (2011), aspirin (75-
162mg/day) should be considered for primary prevention of cardiovascular disease in type 
2 diabetes patients for men (>50 years) and women (>60 years) with at least one additional 
major risk factor (family history of cardiovascular disease, hypertension, smoking, 
dyslipidemia or albuminuria). The other types of antiplatelet agents either alone or 
combination with aspirin therapy has no established role in primary prevention of 
cardiovascular disease in type 2 diabetes patients. In contrast, aspirin should not be 
recommended for CVD prevention for diabetes patients with low CVD risk (10-year CVD 
risk <5%, such as in men <50 and women <60 years of age with no additional CVD risk 
factors, since the potential adverse effects from bleeding likely outweigh the potential 
benefits (ADA, 2011). A same recommendation goes to type 2 diabetes patients with 
multiple other risk factors (e.g. 10-year risk 5-10%), in which clinical judgment is required 
(American Diabetes Association, 2011).  
7. Monitoring of aspirin efficacy and adverse effects 
Aspirin once daily (75-100 mg) is recommended in primary prevention of CVD in type 2 
diabetes patients when antiplatelet prophylaxis has a favorable benefit/risk profile (Patrono 
et al., 2004). For effectiveness of primary prevention strategy, patients should be followed on 
a regular basis and examined for signs and symptoms of any cardiovascular diseases. In 
consideration of dose-dependent GI toxicity and its potential impact on compliance, 
physicians are encouraged to use the lowest dose of aspirin that was shown to be effective in 
each clinical setting (Patrono et al., 2001). Aspirin should not be given to patients with 
gastrointestinal ulcerations; best tolerated after food. In conclusion, bleeding and gastrointestinal 
complications are the most common adverse effects of aspirin. Thus, the patients on aspirin 
should be monitored for stomach pain, heartburn, nausea and bleeding tendency.  
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Dyslipidemia is one of the risk factors for acquiring cardiovascular disease in patients 
with type 2 diabetes. In absent for contraindication, type 2 diabetes patients with 
dyslipidemia are eligible for primary prevention of cardiovascular disease although the 
routine use has not been documented. Aspirin plays a key role in primary prevention 
strategy of cardiovascular disease in type 2 diabetes patients. With limited studies and 
evidence for other antiplatelet agents, their role in primary prevention has not been 
established. 
9. Summary 
Dyslipidemia is one of the major risk factors for macrovascular disease leading to CVD in 
type 2 diabetes. 
In type 2 diabetes patients with dyslipidemia, alteration in lipid distribution and platelet 
abnormalities increased risk of acquiring CVD. 
Patients with type 2 diabetes with one of the following; dyslipidemia, family history of 
coronary heart disease, hypertension, smoking and albuminuria are at increased risk of 
CVD, thus eligible for primary prevention strategy of CVD. 
With limited evidence, proper justification and clinical judgments of benefit versus risk, 
aspirin plays a key role as antiplatelet agent in primary prevention of CVD in patients with 
type 2 diabetes with dyslipidemia. 
Patients with type 2 diabetes and dyslipidemia receiving aspirin for primary prevention 
strategy should be monitored for effectiveness of treatment (sign and symptoms of CVD) 
and adverse effects (stomach pain, heartburn, nausea and bleeding tendency). 
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